Regulatory effects of interferon-β on osteopontin and interleukin-17 expression in multiple sclerosis

J Interferon Cytokine Res. 2010 Oct;30(10):751-7. doi: 10.1089/jir.2010.0082.


Multiple sclerosis (MS) is a demyelinating disease characterized by autoimmune inflammation in the central nervous system. Despite over a decade of use of interferon-β (IFN-β) in the treatment of MS, its mechanisms of action are still not fully elucidated. New data now demonstrate that the 2 important proinflammatory cytokines involved in the pathogenesis of MS, osteopontin (OPN) and interleukin-17 (IL-17), are regulated by IFN-β. This review discusses the role of OPN and IL-17 in the development of MS and how the downregulation of the levels of OPN and interleukin-17 contributes to the therapeutic effects of IFN-β in MS.

Publication types

  • Review

MeSH terms

  • Down-Regulation / drug effects
  • Humans
  • Interferon-beta / immunology*
  • Interferon-beta / pharmacology
  • Interferon-beta / therapeutic use*
  • Interleukin-17 / genetics*
  • Interleukin-17 / immunology
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / genetics*
  • Multiple Sclerosis / immunology
  • Osteopontin / genetics*
  • Osteopontin / immunology


  • Interleukin-17
  • Osteopontin
  • Interferon-beta